Europe
Prestigious business award granted in recognition of novel gene synthesis technology
SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at the 10th Annual OBN Awards Ceremony last night.
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular risk reduction.
Citing structural simplification, Pfizer announced it plans to cut its global staffing by about 2 percent. It expects to do so primarily through voluntary layoffs and early retirement through the end of this year and early in 2019.
Shares of Indiana-based Endocyte have shot up more than 50 percent in pre-market trading after Swiss pharma giant Novartis announced it was acquiring the company for $2.1 billion in cash. The deal will allow the company to expand its radiopharmaceuticals business.
Shvabe Holding, part of Russian State Corporation Rostec, is ready to assist its Indian partners in the creation, equipping and reequipping of hospitals and medical centers. The Holding is prepared to supply the country with a wide range of high-tech medical products, in fields ranging from diagnostics to VR rehabilitation.
OBN (UK) Ltd is delighted to announce the winners of the 2018 OBN Awards.
First public trial of DnaNudge’s technology has today been launched to study effects of DNA-based food choices for pre-diabetic individuals
Potential CHMP opinion moved from Q4 2018 into H1 2019
PRESS RELEASES